Mark Leibowitz
Impact in
- Pharmacology top 10%
- Cholinesterase and Neurodegenerative Diseases
- Treatment of Major Depression
- Pharmacology and Obesity Treatment
- Psychiatry and Mental health top 10%
Papers in
-
- Cholinesterase and Neurodegenerative Diseases 2
- Pharmacology and Obesity Treatment 2
-
- Epilepsy research and treatment 2
- Co-authors
- Larry Ereshefsky (5 shared papers)S. S. Jhee (4 shared papers)G Sędek (1 shared paper)Gilbert Lefèvre (1 shared paper)Heinz Schmidli (1 shared paper)Silke Appel‐Dingemanse (1 shared paper)Albert Enz (1 shared paper)F. Pommier (1 shared paper)
- Journals
- Clinical Therapeutics (2 papers)Neurology (2 papers)The Journal of Clinical Pharmacology (2 papers)Journal of Cardiovascular Pharmacology (2 papers)Journal of Clinical Sleep Medicine (1 paper)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Mark Leibowitz
16 papers receiving 521 citations
Peers
Comparison fields: 5 of 80
- Pharmacology 154
- Psychiatry and Mental health 86
- Neurology 84
- Biological Psychiatry 12
- Physiology 98
Countries citing papers authored by Mark Leibowitz
This map shows the geographic impact of Mark Leibowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Leibowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Leibowitz more than expected).
Fields of papers citing papers by Mark Leibowitz
This network shows the impact of papers produced by Mark Leibowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Leibowitz. The network helps show where Mark Leibowitz may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Leibowitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 109 | |
| 2 | 2002 | 64 | |
| 3 | 2009 | 55 | |
| 4 | 2002 | 52 | |
| 5 | 2007 | 52 | |
| 6 | 2008 | 50 | |
| 7 | 2007 | 31 | |
| 8 | 2001 | 31 | |
| 9 | 2006 | 29 | |
| 10 | 2014 | 27 | |
| 11 | 2004 | 18 | |
| 12 | 2024 | 11 | |
| 13 | 2012 | 7 | |
| 14 | 2012 | 7 | |
| 15 | 2016 | 6 | |
| 16 | 2013 | 1 |
About Mark Leibowitz
Mark Leibowitz is a scholar working on Pharmacology, Psychiatry and Mental health, Molecular Biology, Cellular and Molecular Neuroscience and Cardiology and Cardiovascular Medicine, having authored 16 papers that have together received 550 indexed citations. Recurring topics across this work include Cholinesterase and Neurodegenerative Diseases (2 papers), Neuroscience and Neuropharmacology Research (2 papers), Pharmacology and Obesity Treatment (2 papers), Epilepsy research and treatment (2 papers), Diabetes Management and Research (1 paper), Cardiac electrophysiology and arrhythmias (1 paper), Hormonal and reproductive studies (1 paper) and Context-Aware Activity Recognition Systems (1 paper). The work is most often cited by research in Pharmacology (154 citations), Psychiatry and Mental health (86 citations), Neurology (84 citations), Biological Psychiatry (12 citations) and Physiology (98 citations). Mark Leibowitz has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Larry Ereshefsky, S. S. Jhee, G Sędek, Gilbert Lefèvre, Heinz Schmidli, Silke Appel‐Dingemanse, Albert Enz, F. Pommier, Michael A. Derby and Celedon Gonzales. Their work appears in journals such as Clinical Therapeutics, Neurology, The Journal of Clinical Pharmacology, Journal of Cardiovascular Pharmacology and Journal of Clinical Sleep Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.